

# Radha Rajasingham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/253894/publications.pdf>

Version: 2024-02-01

67  
papers

5,527  
citations

236612

25  
h-index

118652

62  
g-index

70  
all docs

70  
docs citations

70  
times ranked

8040  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 873-881.	4.6	1,559
2	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 517-525.	13.9	1,081
3	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 623-631.	2.0	444
4	Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2014, 370, 2487-2498.	13.9	387
5	Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast. <i>Emerging Infectious Diseases</i> , 2014, 20, 45-53.	2.0	253
6	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa130.	0.4	160
7	The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1607-1614.	2.9	145
8	Integrating Cryptococcal Antigen Screening and Pre-Emptive Treatment into Routine HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, e85-e91.	0.9	143
9	Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	115
10	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	2.9	103
11	Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001316.	3.9	79
12	Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 274-279.	0.6	60
13	Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. <i>Clinical Infectious Diseases</i> , 2017, 65, 2126-2129.	2.9	54
14	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 766-769.	2.3	46
15	Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. <i>Metabolic Brain Disease</i> , 2014, 29, 269-279.	1.4	45
16	HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. <i>Journal of Infectious Diseases</i> , 2019, 219, 877-883.	1.9	43
17	Cost-effectiveness of Treatment Regimens for <i>Clostridioides difficile</i> Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. <i>Clinical Infectious Diseases</i> , 2020, 70, 754-762.	2.9	42
18	Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. <i>Current Tropical Medicine Reports</i> , 2015, 2, 81-89.	1.6	38

#	ARTICLE	IF	CITATIONS
19	The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015–2017. Open Forum Infectious Diseases, 2019, 6, ofz419.	0.4	38
20	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa500.	0.4	38
21	Symptoms of COVID-19 Outpatients in the United States. Open Forum Infectious Diseases, 2020, 7, ofaa271.	0.4	38
22	Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis. PLoS ONE, 2019, 14, e0210105.	1.1	37
23	Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/μL: A Stepped-Wedge, Cluster-Randomized Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 182-189.	0.9	35
24	Reconsidering Cryptococcal Antigen Screening in the U.S. Among Persons With CD4 <100 cells/mcL. Clinical Infectious Diseases, 2012, 55, 1742-1744.	2.9	30
25	A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 231-238.	0.9	28
26	Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. BMC Infectious Diseases, 2017, 17, 225.	1.3	25
27	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19—A Call for Clinical Trials. Open Forum Infectious Diseases, 2020, 7, ofaa350.	0.4	25
28	Evaluation of Serum Cryptococcal Antigen Testing Using Two Novel Semiquantitative Lateral Flow Assays in Persons with Cryptococcal Antigenemia. Journal of Clinical Microbiology, 2020, 58, .	1.8	25
29	Performance of Cryptococcal Antigen Lateral Flow Assay Using Saliva in Ugandans with CD4 <100. PLoS ONE, 2014, 9, e103156.	1.1	22
30	Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2015, 2, ofv157.	0.4	22
31	Evaluation of a point-of-care immunoassay test kit – StrongStep™ for cryptococcal antigen detection. PLoS ONE, 2018, 13, e0190652.	1.1	22
32	The Effect of Infectious Diseases Consultation on Mortality in Hospitalized Patients With Methicillin-Resistant Staphylococcus aureus, Candida, and Pseudomonas Bloodstream Infections. Open Forum Infectious Diseases, 2020, 7, ofaa010.	0.4	21
33	Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa. Clinical Infectious Diseases, 2020, 71, 525-531.	2.9	20
34	Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda. Wellcome Open Research, 2018, 3, 64.	0.9	20
35	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Canadian Journal of Anaesthesia, 2020, 67, 1201-1211.	0.7	19
36	Ending deaths from HIV-related cryptococcal meningitis by 2030. Lancet Infectious Diseases, The, 2021, 21, 16-18.	4.6	18

#	ARTICLE	IF	CITATIONS
37	Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	17
38	Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020, 71, e45-e49.	2.9	17
39	Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapyâ€“Experienced Ugandans With Virologic Failure. <i>Clinical Infectious Diseases</i> , 2020, 71, 1726-1731.	2.9	15
40	Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006â€“2016. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx077.	0.4	14
41	Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. <i>BMC Neurology</i> , 2017, 17, 110.	0.8	13
42	Cryptococcal Antigen Screening and Preemptive Treatmentâ€”How Can We Improve Survival?. <i>Clinical Infectious Diseases</i> , 2020, 70, 1691-1694.	2.9	12
43	Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. <i>Medical Mycology</i> , 2020, 58, 1037-1043.	0.3	12
44	A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda. <i>Medicine (United States)</i> , 2018, 97, e11722.	0.4	10
45	Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. <i>Medical Mycology</i> , 2020, 58, 282-292.	0.3	10
46	Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0086021.	1.8	10
47	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1266.	0.3	9
48	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa602.	0.4	9
49	Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent <i>Clostridioides difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2022, 75, 1602-1609.	2.9	8
50	Female Contributions to Infectious Diseases Society of America Guideline Publications. <i>Clinical Infectious Diseases</i> , 2019, 68, 893-894.	2.9	7
51	HIV care: ART adherence support and cryptococcal screening. <i>Lancet, The</i> , 2015, 385, 2128-2129.	6.3	6
52	Successful Conservative Management of Bilateral Renal Mucormycosis. <i>Urology</i> , 2018, 120, 2-5.	0.5	6
53	AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019, 9, e026288.	0.8	6
54	Correlation between Blood and CSF Compartment Cytokines and Chemokines in Subjects with Cryptococcal Meningitis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	1.4	5

#	ARTICLE	IF	CITATIONS
55	New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs. <i>Clinical Infectious Diseases</i> , 2019, 69, 732-732.	2.9	4
56	Change in Plasma Cryptococcal Antigen Titer Is Not Associated With Survival Among Human Immunodeficiency Virusâ€infectected Persons Receiving Preemptive Therapy for Asymptomatic Cryptococcal Antigenemia. <i>Clinical Infectious Diseases</i> , 2020, 70, 353-355.	2.9	3
57	Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting. <i>Research Involvement and Engagement</i> , 2020, 6, 49.	1.1	3
58	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 0, 6, 140.	0.9	3
59	Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. <i>Medical Mycology</i> , 2021, 59, 712-719.	0.3	3
60	Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa530.	0.4	3
61	Reply to Neves. <i>Clinical Infectious Diseases</i> , 2021, 73, e1772-e1774.	2.9	2
62	Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries. <i>Medical Mycology</i> , 2022, 60, .	0.3	1
63	Determinants of cryptococcal antigen (CrAg) screening uptake in Kampala, Uganda: An assessment of health center characteristics. <i>Medical Mycology</i> , 2022, 60, .	0.3	1
64	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 0, 6, 140.	0.9	1
65	Reply to Author. <i>Clinical Infectious Diseases</i> , 2022, 74, 563-563.	2.9	0
66	Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0
67	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 0, 6, 140.	0.9	0